ANN ARBOR — Apervita Inc., a Chicago-based health analytics and data community and marketplace, announced that the University of Michigan has joined the Apervita community to commercialize the university’s portfolio of medical algorithms, assessments and protocols.
Through Apervita, an agreement concluded with the university’s technology transfer office will enable university clinicians and researchers to write and publish their research in an analytics format that can be offered to any health enterprise through the Apervita marketplace.
“The University of Michigan is a prolific research organization and their technology transfer office has compiled a valuable inventory of health intellectual property,” said Apervita CEO Paul Magelli. “Apervita provides them with the ability to unlock it and commercialize it, quickly sharing it with other institutions. With Apervita, their doctors and researchers are able to publish their knowledge as computable analytics, enabling other health professionals everywhere to subscribe and apply it in their work. This approach facilitates the rapid on-boarding, publishing and improvement of health analytics direct from the original authors, who after all are the experts. In this way, not only will the users benefit from their expertise, but the university will fully retain control of its intellectual property, while generating a source of revenue.”
Over time, UM plans to make available a broad selection of its health analytics through Apervita. Initially they will focus on the areas of cardiology, diabetes, and wellness.
UM’s research effort is among the largest of any university in the country — more than $1.3 billion a year. UM Tech Transfer, the University unit responsible for transferring research discoveries to business and venture partners, launches an average of 12 start-ups, and signs over 100 agreements with businesses annually. These activities have led to the launch of over 100 new start-up companies since 2000, including HealthMedia, Compendia Biosciences and
Arbor Networks, and the adoption of several major technologies, such as the FluMist inhalable flu vaccine and the IntraLase lasik eye surgery system. More at www.techtransfer.umich.edu.